抗原结合和信号传导受损影响双特异性CD19和CD79a嵌合抗原受体功能
研究探讨靶向CD19和CD79a/b的双特异性CAR-T细胞能否克服抗原逃逸。免疫组化显示84.3%淋巴瘤表达CD79a/b,其中87.3%共表达CD19。双特异性CAR-T可防止CD19丢失淋巴瘤异种移植模型中抗原阴性细胞生长,但串联和双顺反子CAR-T对仅表达单一抗原的肿瘤效果不及单特异性CAR-T,并分别存在抗原结合减少和下游信号磷酸化降低的缺陷。
要点
- 84.3%淋巴瘤病例免疫组化表达CD79a/b,其中87.3%共表达CD19。
- 双特异性CAR-T可防止CD19丢失淋巴瘤异种移植模型中抗原阴性细胞生长。
- 串联和双顺反子CAR-T对仅表达CD19或CD79的肿瘤效果不及相应单特异性CAR-T。
核心结论
- 尽管增加了特异性,串联和双顺反子CAR-T细胞表现出不同缺陷,损害对表达单一抗原肿瘤细胞的识别。
- 数据支持靶向多种B细胞抗原以提高疗效,并识别双特异性受体设计需改进之处。
研究设计与样本
- 研究构建了串联、双顺反子和混合产物三种CD79a-CD19或CD79b-CD19双特异性CAR-T细胞。
- 使用CD19丢失淋巴瘤异种移植模型评估双特异性CAR-T对抗原阴性细胞生长的作用。
- 比较双特异性与单特异性CD19或CD79a CAR-T对仅表达相应单一抗原肿瘤的治疗效果。
- 采用免疫组化检测淋巴瘤病例中CD79a/b和CD19的表达。
主要发现
- 免疫组化显示84.3%的淋巴瘤病例表达CD79a/b,87.3%的CD79ab阳性肿瘤共表达CD19。
- 双特异性CAR-T细胞 prevented 抗原阴性细胞在CD19丢失淋巴瘤异种移植模型中的生长。
- 串联和双顺反子CAR-T细胞对仅表达CD19或CD79的肿瘤效果不及单特异性CD19或CD79a CAR-T细胞。
- 与单特异性CAR-T细胞相比,表达串联CAR的T细胞对每种靶抗原的结合减少。
- 与单特异性CAR-T细胞相比,表达双顺反子CAR载体的T细胞下游CAR信号分子磷酸化减少。
关键数值与推荐
- 84.3%淋巴瘤病例免疫组化表达CD79a/b。
- 87.3%的CD79ab阳性肿瘤共表达CD19。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy with CD19-directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR T-cell therapy. Engineering bispecific CAR T cells that target 2 tumor antigens could overcome antigen-negative escape. We found that CD79a and b, which are heterodimeric components of the B-cell receptor, were expressed on 84.3% of lymphoma cases using immunohistochemistry, and 87.3% of CD79ab-positive tumors also coexpressed CD19. We generated 3 bispecific permutations: tandem, bicistronic, and pooled products of CD79a-CD19 or CD79b-CD19 CAR T cells and showed that bispecific CAR T cells prevented the outgrowth of antigen-negative cells in a CD19-loss lymphoma xenograft model. However, tandem and bicistronic CAR T cells were less effective than monospecific CD19 or CD79a CAR T cells for the treatment of tumors that only expressed CD19 or CD79, respectively. When compared with monospecific CAR T cells, T cells expressing a tandem CAR exhibited reduced binding of each target antigen, and T cells expressing a bicistronic CAR vector exhibited reduced phosphorylation of downstream CAR signaling molecules. Our study showed that despite added specificity, tandem and bicistronic CAR T cells exhibit different defects that impair recognition of tumor cells expressing a single antigen. Our data provide support for targeting multiple B-cell antigens to improve efficacy and identify areas for improvement in bispecific receptor designs.
引用
- Leung I, Templeton ML, Lo Y, et al. Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. Blood Adv. 2023. PMID: 36469024. doi:10.1182/bloodadvances.2022008559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。